Program

 

Tuesday, 27 November, 2018

  12:30Registration
 Opening Session
Chairs: Charles Boucher & Raymond F. Schinazi
  14:00Opening remarks and presentation of Gertrude Elion Distinguished Lecturer Award
Raymond F. Schinazi
Emory University, USA
  14:10Presentation of Gertrude Elion Distinguished Lecturer Award recipient
Rowena Johnston
amfAR, USA
  14:20Gertrude Elion Distinguished Lecturer Award Lecture
Innovation with an Impact: Development of HIV and TB drugs
Paul Stoffels
Johnson and Johnson, USA
   
 Session 1: Cure Session 1: Basic science and pre-clinical developments
Chairs: Steven Deeks & Rowena Johnston
  14:50State of the Art Lecture: Molecular basis for HIV latency
Jonathan Karn
Case Western Reserve University, USA
  15:20Understanding barriers to HIV cure
Robert Siliciano
Johns Hopkins University, USA
  15:40HIV reservoir dynamics: Implications for HIV latency establishment and reversal
Deanna Kulpa
Emory University, USA
  16:00BREAK 
   
 Session 2: Cure Session 2: Clinical Implementation
Chairs: Mario Stevenson & Jonathan Karn
  16:30State of the Art Lecture: Harnessing the immune system to eliminate and/or control HIV
Steve Deeks
University of California San Francisco, USA
  17:00Evidence of a macrophage reservoir in HIV persistence under effective antiretroviral therapy
Mario Stevenson
University of Miami, USA
  17:20Baricitinib reverses HIV associated neurocognitive disorders and reservoir seeding in a SCID mouse model
Christina Gavegnano
Emory University, USA 
  17:40Potential for HIV cure by stem cell transplantation (IciStem)
Monique Nijhuis
University Medical Center Utrecht, the Netherlands 
   
  ORAL ABSTRACT SESSION 1
Chairs: Savita Pahwa & Deanna Kulpa
  18:00The inhibitor of apoptosis proteins antagonist DEBIO 1143 is a promising HIV-1 latency reversal agent (#1)
Philippe Gallay
The Scripps Research Institute, USA
  18:10Oral ABX464 has a dose dependent reduction in the HIV-1 DNA reservoir in CD4+ Peripheral Blood T Cells (#2)
Jean-Marc Steens
Abivax, France
  18:20Differential detection of M184V/I between plasma historical HIV genotypes and proviral DNA from PBMCs (#3)
Nicolas Margot
Gilead Sciences, USA
  18:30HIV-1 DNA resistance testing supports STR/2DR treatment simplification options (#4)
Charles Walworth  
Monogram Biosciences/labcorp, USA 
  18:40End of day one
  Welcome Reception
   
  

Wednesday, 28 November 2018

Chairs: Raymond F. Schinazi & Hiroaki Mitsuya

  8:10Presentation of Barry-Wainberg DART Achievement Award and recipient
Charles Boucher
Erasmus MC
  8:20Barry-Wainberg DART Achievement Award Lecture: Overview of the research conducted at the Irsicaixa Foundation
Bonaventura Clotet
Universitat Autònoma de Barcelona, Spain
   
 Session 3: New drugs and improved formulations
Chairs: Leor S. Weinberger & Monique Nijhuis
  8:50State of the Art Lecture: Rational design of doravirine (DOR): From bench to patients
Daria Hazuda
Merck, USA
  9:20Injectable ART: Advantages and disadvantages
Michael Saag
University of Alabama, USA
  9:40Polypharmacy in an aging population and implications for antiretroviral therapy
Charles Flexner
Johns Hopkins University, USA
  10:00Panel discussion 
  10:15BREAK 
   
 Session 4: Cutting edge developments in therapeutic and curative strategies
Chairs: Mikaela Müller-Trutwin & Daria Hazuda
  10:35State of the Art Lecture: Trispecific Antibodies for the Prevention and Treatment of HIV Infection and Cancer
Gary Nabel
Sanofi, France
  11:05Long-term virologic suppression following AAV delivery of anti-HIV monoclonal antibodies
Ron Desrosiers
University of Miami, USA
  11:25A post-transcriptional feedback mechanism for noise suppression and fate stabilization
Leor S. Weinberger
UCSF, USA
  11:45Structural basis of HIV-1 inhibition by the nucleotide-competing reverse transcriptase inhibitor indolopyridone-1 (INDOPY-1)
Eddy Arnold
Rutgers University, USA
  12:05Discovery of an unprecedentedly potent HIV-1 protease inhibitor, GRL-0142, and its biological features
Hiroaki Mitsuya
NIH, USA & National Center for Global Health & Medicine, Japan
  12:25Panel discussion 
  12:40Lunch + Free afternoon 
   
  15:00Poster Reception
   
 Session 5: Inflammation, NeuroAIDS and immunotherapy
Chairs: Ron Desrosiers & Charles Flexner
  16:00State of the Art Lecture: Regulation of viral reservoirs: which role for NK cells? 
Mikaela Müller-Trutwin
Institut Pasteur, France
  16:30Inflammation, HIV and aging
Savita Pahwa
University of Miami, USA
  16:50Hispanic/Latino longitudinal cohort of HIV-seropositive women and neurological complications
Loyda M. Melendez
University of Puerto Rico, Puerto Rico
   
  ORAL ABSTRACT SESSION 2
Chairs: Michael Saag & Robert Siliciano
  17:10Prevalence of neuropsychiatric conditions among HIV positive compared to HIV negative commercially insured individuals in 2017 (#5)
Joshua Cohen
IQVIA, USA
  17:20Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in a rapid initiation model of care for HIV-1 infection: Week 24 interim analysis of the DIAMOND study (#6)
Keith Dunn
Janssen Scientific Affairs, LLC, USA
  17:30Initial viral load decline and response rates by baseline viral load strata with dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: Pooled results from the GEMINI studies (#7)
Michael Aboud
ViiV Healthcare, UK
  17:40A novel HIV protease inhibitor, GRL-142, binds to integrase and potently blocks INSTIresistant HIV-1 variants (#4)
Manabu Aoki
National Cancer Institute, United States
  17:50End of day two
  18:30Conference Dinner
   
  

Thursday, 29 November 2018

 Session 6: Emerging viruses: Epidemiology, diagnosis
Chairs: Mauro Teixeira &  Mehul Suthar
  8:10State of the Art Lecture: Post-natal Zika virus infections
Ann Chahroudi
Emory University, USA
  8:40Zika virus infection and neutralizing human monoclonal antibodies
David Watkins
University of Miami, USA
  9:00Advances in vaccine and therapeutics development against Ebola virus
Sina Bavari
United States Army Medical Research Institute of Infectious Diseases, USA
  ORAL ABSTRACT SESSION 3: Therapeutics and novel study models
Chairs: Matthias Götte & Ladislau Kovari
  9:20Rhesus macaque model of SIV/SHIV-Zika co-infection (#9)
Siddappa Byrareddy
University of Nebraska Medical Center, USA
  9:30Galidesivir, a broad-spectrum adenosine analog direct-acting antiviral drug, abrogates viremia in rhesus macaques challenged with Zika virus (#10)
James Whitney
Beth Israel Deaconess Medical Center, Harvard Medical School, USA
  9:40BREAK
   
 Session 7: Emerging viruses: treatment
Chairs: Ann Chahroudi &  David Watkins
  10:10State of the Art Lecture: Disease modifying drugs for infectious diseases such as Dengue and Zika
Mauro Teixeira
Universidade Federal de Minas Gerais, Brazil
  10:40Zika and other emerging viruses in the Americas
Mehul Suthar
Emory University, USA
  11:00Development of protease inhibitors against norovirus and other emerging viruses
Ladislau Kovari
Wayne State University, USA
  11:20In vitro study of Ebola and other polymerases
Matthias Götte
University of Alberta, Canada
  11:40Panel Discussion 
  12:00Closing remarks
Raymond Schinazi
Emory University
  12:10 Meeting adjournment and light lunch
   

 RespiDart starts in the afternoon.